ASCO-Update 2005 - Neuigkeiten vom 41. Meeting der American Society of Clinical Oncology/ASCO 2005

Zusammenfassung

Die onkologische Therapie gastrointestinaler Tumore unterliegt durch die Einführung neuer Chemotherapeutika und den zunehmenden Einsatz von „Targeted Therapies” einem raschen Wandel. Wir möchten in der folgenden Übersicht die wichtigsten neuen klinischen Studien zu Ösophagus-, Magen-, kolorektalen, Pankreas-, Leber- und Gallenwegskarzinomen vorstellen und bewerten, die auf dem diesjährigen Meeting der American Society of Clinical Oncology präsentiert wurden.

Abstract

Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review provides an overview of the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.

Schlüsselwörter

Ösophaguskarzinom - Magenkarzinom - kolorektales Karzinom - Pankreaskarzinom - Leberzellkarzinom - Gallenwegskarzinom - Targeted Therapies - klinische Studien

Key words

Esophageal cancer - gastric cancer - colorectal cancer - pancreatic cancer - hepatobiliary cancer - targeted therapies - clinical trials

Literatur
(angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)

• 1 Al-Batran S E, Stöhlmacher J, Probst S. et al . Fluorouracil, leukovorin and oxaliplatin (FLO) versus fluorouracil, leukovorin and cisplatin (FLP) as a first line therapy for patients with advanced gastric cancer; first interim analysis of a randomsed multicenter phase II study.  Proc ASCO. 2005;  A 4015
• 2 Andre T, Boni C, Mounedji-Boudiaf L. et al . Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.  N Engl J Med. 2004;  43 2343-2351
• 3 Arkenau H, Schmoll H, Kubicka S. et al . Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis.  Proc ASCO. 2005;  A 3507
• 4 Barbare J C, Bouché O, Bonnetain F. et al . Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001 - 01 CHOC).  Proc ASCO. 2005;  A 4036
• 5 Berlin J D, Catalano P, Thomas J P. et al . 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.  J Clin Oncol. 2002;  43 3270-3275
• 6 Boige V, Raoul J, Pignon J. et al . Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): a phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003 - 03 trial).  Proc ASCO. 2005;  A 4128
• 7 Bosset J F, Calais G, Mineur L. et al . Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22 921 trial.  Proc ASCO. 2005;  A3505
• 8 Cascinu S, Labianca R, Barone C. et al . High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen.  Proc ASCO. 2005;  A4023
• 9 Chua Y J, Cunningham D. Adjuvant treatment for resectable pancreatic cancer.  J Clin Oncol. 2005;  43 4532-4537
• 10 Cunningham D, Allum D, Stenning, Weeden S. for the NCRI Upper GI Clinical Studies Group .Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Finasl results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93 793 971). Proc ASCO 2005: A4001
• 11 Dank M, Zaluski J, Barone C. et al . Randomized phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients.  Proc ASCO. 2005;  A 61
• 12 de Gramont A, Boni C, Navarro M. et al . Oxaölipaltin/5FU/LV in the adjuvant treatment of stage II and Stage III colon cancer: Efficacy results with a mdian follow-up of 4 years.  Proc ASCO. 2005;  A 3501
• 13 Díaz R ubio E, Tabernero J, van Cutsem E. et al . Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.  Proc ASCO. 2005;  A3535
• 14 Doffoel M, Vetter D, Bouche O. et al . Multicenter randomized Phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients.  Proc ASCO. 2005;  A4128
• 15 Duyster J, Lorenzen S, Kullmann F. et al . Oxaliplatin plus 5FU/folinic acid (FUIFOX Regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenterr Phase II STOMOX Trial.  Proc ASCO. 2005;  A 4016
• 16 Eberl T, Graeven U, Heike M. et al . ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003.  Z Gastroenterol. 2003;  43 1039-1045
• 17 Gebbia N, Verderame F, Di Leo R. et al . A phase II study of Oxaliplatin (O) and Gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers.  Proc ASCO. 2005;  A 4132
• 18 Gerard J, Bonnetain F, Conroy T. et al . Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3 - 4 rectal cancers : results of the FFCD 9203 randomized trial.  Proc ASCO. 2005;  A 3504
• 19 Giantonio B J, Catalano P J, Meropol N J. et al . High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200.  Proc ASCO. 2005;  A 2
• 20 Glover K Y, Thomas M B, Brown T D. et al . A Phase II Study of Oxaliplatin and Capecitabine (XELOX) in Patients with Unresectable Cholangiocarcinoma, including Carcinoma of the Gallbladder and Biliary Tract.  Proc ASCO. 2005;  A 4123
• 21 Graeven U, Heike M, Hohler T. et al . ASCO update - highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004.  Z Gastroenterol. 2004;  43 1416-1424
• 22 Hecht J R, Trarbach T, Jaeger E. et al . A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222 584 or placebo (CONFIRM-1).  Proc ASCO. 2005;  A 3
• 23 Heinemann V, Hoehler T, Seipelt G. et al . Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer.  Proc ASCO. 2005;  A 4030
• 24 Herrmann R, Bodoky G, Ruhstaller T. et al . Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG).  Proc ASCO. 2005;  A 4010
• 25 Hochster H S, Welles L, Hart L. et al . Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies.  Proc ASCO. 2005;  A3515
• 26 Kawashima M, Kagami Y, Oguchi M. et al . A phase II trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus.  Proc ASCO. 2005;  A 8026
• 27 Kinoshita T, Nakajima T, Ohashi Y. Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: Results of a randomized trial by national surgical adjuvant study of gastric cancer.  Proc ASCO. 2005;  A 4021
• 28 Kozloff M, Cohn A, Christiansen N. et al . Safety of bevacizumab (BV, Avastin™) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) - preliminary results from a larger registry in the US.  Proc ASCO. 2005;  A 3566
• 29 Liang H. Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in Inoperable Pancreatic Cancer: A meta-analysis.  Proc ASCO. 2005;  A 4110
• 30 Lin A Y, Fisher G, So S. et al . A phase II study of imatinib mesylate (IM) in patients (pts) with unresectable hepatocellular carcinoma (HCC).  Proc ASCO. 2005;  A 4223
• 31 Moiseyenko V, Ajani J A, Tjulandin S. et al . Final results of a randomized controlled phase III trial comparing docetaxel (D), combined with cisplatin (C), 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC).  Proc ASCO. 2005;  A 4002
• 32 Moore M J, Goldstein D, Hamm J. et al . Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG].  Proc ASCO. 2005;  A 1
• 33 Muro K, Najima M, Hamaguchi T. et al . Definitive chemoradiotherapy followed by salvage therapy for locoregional failure might be a standard treatment option for stages I-III esophageal squamous cell carcinoma.  Proc ASCO. 2005;  A 4069
• 34 Neuhaus P, Oettle H, Post S. et al . A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer.  Proc ASCO. 2005;  A 4013
• 35 Oettle H, Pelzer U, Stieler J. et al . Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive careversus best supportive care alone (BSC) in second-line therapy ofgemcitabine-refractory advanced pancreatic cancer (CONKO 003).  Proc ASCO. 2005;  A 4031
• 36 Park J O, Kang W K, Kim T. et al . A phase II trial of gemcitabine plus cisplatin (GP) in patients with inoperable biliary tract cancer (BTC).  Proc ASCO. 2005;  A 4133
• 37 Riess H, Helm A, Niedergethmann M. et al . A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer.  Proc ASCO. 2005;  A 4009
• 38 Rowland K M, Pitot H C, Sargent D J. et al . Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy.  Proc ASCO. 2005;  A 3519
• 39 Sakamoto J, Morita S, Tsuburaya A. et al . Efficacy of adjuvant chemotherapy with oral fluorinated pyrimidines for patients with curatively resected gastric cancer. A meta-analysis of centrally randomized controlled clinical trials.  Proc ASCO. 2005;  A 4022
• 40 Sauer R, Becker H, Hohenberger W. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer.  N Engl J Med. 2004;  43 1731-1740
• 41 Schalhorn A, Ludwig F, Quietzsch D. et al . Phase III Trial of Irinotecan Plus Oxalipatin (IROX) Versus Irinotecan Plus 5-FU/Folinic Acid (FOLFIRI) as First-Line Treatment of Metastatic Colorectal Cancer (CRC): The FIRE-Trial.  Proc ASCO. 2005;  A 3516
• 42 Shapiro J, Marshall J, Karasek P. et al . G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study.  Proc ASCO. 2005;  A 4012
• 43 Skillings J R, Johnson D H, Miller K. et al . Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy.  Proc. ASCO. 2005;  A 3019
• 44 Tsavaris N, Kosmas C, Skopelitis H. et al . Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.  Invest New Drugs. 2005;  43 369-375
• 45 Van Cutsem E, Labianca R, Hossfeld D. et al . PETACC 3. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3).  Proc ASCO. 2005;  A 8
• 46 Wolmark N, Wieand H S, Kuebler J P. et al . A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07.  Proc ASCO. 2005;  A 3500
• 47 Ychou M, Raoul J, Douillard J. et al. for the GI Group of the FNCLCC and the FFCD .A phase III randomized trial of LV5FU2 +CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Proc ASCO 2005: A 3502
• 48 Zhu A X, Sahani D, Norden-Zfoni A. et al . A Phase II Study of Gemcitabine, Oxaliplatin in Combination with Bevacizumab (GEMOX-B) in Patients with Hepatocellular Carcinoma.  Proc ASCO. 2005;  A 4120